MENLO PARK, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter and fiscal year ended December 31, 2025. Fourth quarter and full year ...
Genomics company Pacific Biosciences of California (NASDAQ:PACB) in Q3 CY2025, with sales falling 3.8% year on year to $38.44 million. Its non-GAAP loss of $0.12 per share was 14.2% above analysts’ ...
Gross margin, operating expenses, net loss, and net loss per share are reported on a GAAP and non-GAAP basis. The non-GAAP measures are described below and reconciled to the corresponding GAAP ...
Hosted on MSN
PacBio (NASDAQ:PACB) reports strong Q4 CY2025
Genomics company Pacific Biosciences of California (NASDAQ:PACB) reported Q4 CY2025 results , with sales up 13.8% year on year to $44.65 million. Its non-GAAP loss of $0.12 per share was 10.8% above ...
Gross margin, operating expenses, net income (loss), and net income (loss) per share are reported on a GAAP and non-GAAP basis. The non-GAAP measures are described below and reconciled to the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results